Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types Planegg/Martinsried, August 23, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...